Contraceptive Technology Update – August 1, 2006
August 1, 2006
View Issues
-
New pill options give women choices while changing menstrual bleeding
The Food and Drug Administration (FDA) has just given approval to Seasonique (Duramed Pharmaceuticals; Pomona, NY), an extended-regimen oral contraceptive (OC). -
New research emerges on NuvaRing contraceptive
Women who switch to the NuvaRing contraceptive vaginal ring (Organon, Roseland, NJ) from other forms of hormonal contraception experience reduced hormone-related adverse events, according to results from a study presented at the recent European Society of Contraception in Istanbul, Turkey.1 -
Look at LNG IUS for menorrhagia treatment
Your next patient is a 35-year-old mother of two who is experiencing ongoing heavy menstrual bleeding (menorrhagia). Recently remarried, she says she may want to have a child in the future with her new partner. What are your treatment options? -
Male contraceptive options in the pipeline
For years, the much talked-about male contraceptive pill has remained tantalizingly out of reach. What if the first contraceptive method to reach the commercial market relied on a nonhormonal approach instead? -
Science investigates contraceptive gels
When discussing spermicides with prospective users, family planning providers in the United States have only nonoxynol-9 (N-9) formulations in the contraception arsenal. What if there were other formulations added to the mix? -
Study looks at weight impact on OC efficacy
Research findings have suggested higher failure rates in oral contraceptive (OC) users who are heavy; however, new results from a retrospective analysis of Phase III efficacy data of a popular ethinyl estradiol/norgestimate formulation (Ortho Tri-Cyclen Lo, Ortho McNeil Pharmaceutical; Raritan, NJ) indicate that it is not associated with an increased risk of pregnancy in such women. -
Contraceptive options for overweight women
Unplanned pregnancies carry extra health risks for obese women. In a 2005 study, researchers found that overweight women (BMI 25-29.9) had increased risks of diabetes, hypertension, pre-eclampsia, and cesarean delivery, with even higher risks for obese women (BMI 30 and above).